Table 2.
Autoantibody prevalence in seronegative anti-phospholipid syndrome (SN-APS) patients (n = 36) according to the clinical manifestations
| Autoantibodies (assay) | Total thrombosis n = 21 | Arterial thrombosis n = 8 | Venous thrombosis n = 14 | Recurrent thrombosis n = 6 | Pregnancy morbidity n = 21 |
|---|---|---|---|---|---|
| aCL (TLC) n (%) | 10 (47·6) | 4 (50·0) | 7 (50·0) | 2 (33·3) | 9 (42·8) |
| aLBPA (TLC) n (%) | 9 (42·8) | 4 (50·0) | 6 (42·8) | 3 (50·0) | 9 (42·8) |
| aPE (TLC) n (%) | 6 (28·6) | 3 (37·5) | 4 (28·6) | 2 (33·3) | 6 (28·6) |
| Anti-annexin II (ELISA) n (%) | 3 (14·3) | 0 | 3 (14·3) | 0 | 3 (14·3) |
| No autoantibodies n (%) | 6 (28·6) | 2 (25·0) | 4 (28·6) | 2 (33·3) | 7 (33·3) |
aCL, anti-cardiolipin antibodies; aLBPA, anti-lyso(bis)phosphatidic acid antibodies; aPE, anti-phosphatidylethanolamine antibodies; ELISA, enzyme-linked immunosorbent assay; TLC, thin-layer chromatography.